Merck KGaA Looks To Chinese Medicine For Oncology Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration with China’s Chi-Med is part of an initiative to strengthen Merck’s natural compound expertise, exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Hutchison MediPharma and Eli Lilly Sign New Discovery Deal
BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer
Chi-Med Signs Collaboration With Lilly For Oncology, Inflammation Candidates
Chi-Med's wholly owned research and development subsidiary Hutchison MediPharma will collaborate with Eli Lilly on the discovery and development of pharmaceutical targets in oncology and inflammation, Chi-Med announced Aug. 20
Chi-Med Signs Collaboration With Lilly For Oncology, Inflammation Candidates
Deal could be worth $29 million per candidate, Chi-Med CEO tells “The Pink Sheet” DAILY.